Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis
Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Nicola Maurea(Cancer Institute (WIA)), Iris Parrini(A. O. Ordine Mauriziano di Torino), Nicola Silvestris(University of Messina), Antonio Russo(University of Palermo), Paolo Spallarossa(Ospedale Policlinico San Martino), Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Luigi Tarantini(Santa Maria Nuova Hospital)
Cited by 13
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Prevalence and Prognostic Impact of Non-Cardiac Co-Morbidities in Heart Failure Outpatients with Preserved and Reduced Ejection Fraction: A Community-Based Study
|European Journal of Heart Failure|2018|174
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine
|Annals of Oncology|2010|168
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
|Critical Reviews in Oncology/Hematology|2019|164